<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195817</url>
  </required_header>
  <id_info>
    <org_study_id>15892A</org_study_id>
    <secondary_id>2013-004688-30</secondary_id>
    <nct_id>NCT02195817</nct_id>
  </id_info>
  <brief_title>Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care</brief_title>
  <official_title>Interventional, Open-label Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the reduction in alcohol consumption in patients with alcohol dependence treated
      with 18 mg Selincro® as-needed use, in conjunction with continuous psychosocial support in
      primary care
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      635 patients are planned (total number of patients) with 475 patients treated with Selincro®
      (Cohort A) and 160 patients not treated with Selincro® (Cohort B) to determine the reduction
      in alcohol consumption in patients with alcohol dependence.

      Cohort A will comprise patients who maintain a high drinking risk level (DRL, defined by
      World Health Organization (WHO) as &gt;60g alcohol/day for a man or &gt;40g alcohol/day for a
      woman), or above, in the period between the Screening and Inclusion Visits.

      Cohort B will comprise patients who reduce their alcohol consumption in the period between
      the Screening and Inclusion visits, that is, patients who do not maintain at least a high DRL
      at the Inclusion Visit (and are therefore not eligible for treatment with nalmefene according
      to the SmPC).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to enrolment challenges
  </why_stopped>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of Heavy Drinking Days (HDDs) (days/month)</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Cohort A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Alcohol Consumption (TAC) (g/day)</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinking Risk Level response (RSDRL); defined as a downward shift in Drinking Risk Level (DRL); for patients with a very high DRL at baseline, a shift to medium DRL or below; for patients with a high DRL at baseline, a shift to low DRL or below</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RLDRL response; defined as a downward shift in DRL to low DRL or below</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response defined as ≥70% reduction in TAC</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response defined as 0 to 4 HDDs (days/month)</measure>
    <time_frame>Month 3</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression - Severity of Illness (CGI-S) score</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Global Improvement (CGI-I)</measure>
    <time_frame>Week 12</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>y-glutamyl transferase (y-GT)</measure>
    <time_frame>Week 12</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT)</measure>
    <time_frame>Week 12</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (AST)</measure>
    <time_frame>Week 12</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-item Short-form Health Survey version 2 (SF-36) (only for patients in France and the United Kingdom)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Selincro® 18 mg with continuous psychosocial support: Cohort A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial psychosocial support: Cohort B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Initial psychosocial support followed by usual care practice, 12-week Observational Period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selincro® 18 mg with continuous psychosocial support: Cohort A</intervention_name>
    <arm_group_label>Selincro® 18 mg with continuous psychosocial support: Cohort A</arm_group_label>
    <other_name>nalmefene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Initial psychosocial support: Cohort B</intervention_name>
    <arm_group_label>Initial psychosocial support: Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To ensure the study is broadly representative of primary care clinical practice, minimal
        inclusion and exclusion criteria are imposed with the main exclusion criteria relating to
        contraindications to the prescription of Selincro® and reflecting the indication wording in
        the SmPC.

        Inclusion Criteria:

          -  The patient has alcohol dependence diagnosed according to ICD-10.

          -  The patient has had a high DRL in the 4 weeks preceding the Screening Visit.

          -  The patient is a man or woman, aged ≥18 years.

          -  The patient provides a stable address and telephone number.

        Exclusion Criteria:

          -  The patient has one or more contraindications to the prescription of Selincro®:

               -  hypersensitivity to the active substance or to any of the excipients

               -  taking opioid analgesics

               -  current or recent opioid addiction

               -  acute symptoms of opioid withdrawal

               -  recent use of opioids suspected

               -  severe hepatic impairment (Child-Pugh classification)

               -  severe renal impairment (eGFR &lt;30 ml/min per 1.73 m2)

               -  a recent history of acute alcohol withdrawal syndrome (including hallucinations,
                  seizures, or delirium tremens)

          -  The patient has had &lt;6 HDDs (defined by the European Medicines Agency as a day with an
             alcohol consumption &gt;60g for men or &gt;40g for women) in the 4 weeks preceding the
             Screening Visit.

          -  The patient has physical alcohol withdrawal symptoms and requires immediate
             detoxification for which inpatient treatment is required.

          -  The patient is currently participating or has recently (in the 4 weeks preceding the
             Screening Visit) participated in a treatment or support programme for alcohol-use
             disorders, including Alcohol Anonymous, detoxification treatment, and treatment of
             alcohol withdrawal symptoms, or the patient is already taking nalmefene or has taken
             nalmefene in the 6 months preceding the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FR010</name>
      <address>
        <city>Becon-les-Granits</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR001</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR005</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR009</name>
      <address>
        <city>Cestas</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR012</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR002</name>
      <address>
        <city>Coulounieix-Chamiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR008</name>
      <address>
        <city>La Teste De Buch</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR007</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR011</name>
      <address>
        <city>Narbonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR003</name>
      <address>
        <city>Targon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR006</name>
      <address>
        <city>Tonneins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR004</name>
      <address>
        <city>Vieux Boucau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE002</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE005</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE006</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE003</name>
      <address>
        <city>Jahnsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE004</name>
      <address>
        <city>Jahnsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE011</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE009</name>
      <address>
        <city>Nurnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE010</name>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE001</name>
      <address>
        <city>Wallerfing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE007</name>
      <address>
        <city>Weilburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE008</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES001</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES010</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES003</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES004</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES008</name>
      <address>
        <city>Canet de Mar</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES007</name>
      <address>
        <city>El Prat de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES006</name>
      <address>
        <city>Hospitalet del Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES009</name>
      <address>
        <city>Hospitalet del Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES011</name>
      <address>
        <city>Hospitalet del Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES002</name>
      <address>
        <city>Mataro</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES013</name>
      <address>
        <city>Matar</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES012</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES005</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB011</name>
      <address>
        <city>Ballymena</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB008</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB009</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB004</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB005</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB001</name>
      <address>
        <city>Coatbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB002</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB003</name>
      <address>
        <city>Lanarkshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB006</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB007</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB010</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB106</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004688-30/results</url>
    <description>EMA EudraCT Results: 2013-004688-30</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalmefene</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

